Moving to Laënnec

Published on 28/05/2019

ENYO Pharma will move-in to the new Biosera BioParc Building in Laënnec. It will be a great opportunity as we will be neighbours with Edelris, Erytech Pharma and AB Science. Some CEO, Jean-Yves ORTHOLAND (Edelris), Gil BEYEN (Erytech Pharma) and Jacky VONDERSCHER (ENYO Pharma) recently visited the building under construction.

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)